Abstract:BACKGROUND Partial agonists are a subclass of beta blockers used to treat hypertension in many countries. Partial agonist act by stimulating beta receptors when they are quiescent and blocking beta receptors when they are active. The blood pressure (BP) lowering effect of partial agonist beta blockers has not been quantified. OBJECTIVES To quantify the dose-related effects of various partial agonists beta blockers on systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate versus placebo in patients with primary hypertension. SEARCH METHODS We searched the Hypertension Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, EMBASE and ClinicalTrials.gov for randomized controlled trials up to October 2014. The WHO International Clinical Trials Registry Platform (ICTRP) is searched for inclusion in the Group's Specialised Register. SELECTION CRITERIA Randomized double-blinded placebo-controlled parallel or cross-over trials. Studies must contain a partial agonist monotherapy arm with fixed dose. Patients enrolled into the studies must have primary hypertension at baseline (defined as SBP/DBP > 140/90 mmHg). Duration of studies must be between three to 12 weeks. DATA COLLECTION AND ANALYSIS Two authors (GW and HB) confirmed the inclusion of studies and extracted the data independently. MAIN RESULTS Thirteen randomized double-blinded placebo-controlled trials that examined the blood pressure lowering efficacy of six partial agonists in 605 hypertensive patients were included in this review. Five of the included studies were parallel studies and the other eight were cross-over studies. The overall risk of bias is high in this review due to the small sample size and high risk of detection bias. Pindolol, celiprolol and alprenolol lowered SBP and DBP compared to placebo. Acebutolol lowered SBP but there was no clear evidence that it lowered DBP. There was no clear evidence that pindolol and oxprenolol lowered SBP or DBP. Other than for celiprolol, sample sizes were generally small increasing the uncertainty in findings for individual agents versus placebo. In patients with moderate to severe hypertension, partial agonists (considered as a subclass) lowered peak BP by an average of 8 mmHg systolic (95% CI, -10 to -6, very low quality evidence), 4 mmHg diastolic (95%CI, -5 to -3, very low quality evidence) and reduced heart rate by five beats per minute (95%CI, -6 to -4, very low quality evidence). Higher dose partial agonists did not appear to provide additional BP lowering effects compared to lower dose. The maximum BP lowering effect of the overall subclass occurred at the starting dose. Partial agonists reduced pulse pressure by 4 mmHg (95% CI, -5 to -2, very low evidence). Only one study reported withdrawal due to adverse effects, the risk ratio (95% confidence interval) was 0.72 (0.07, 7.67). AUTHORS' CONCLUSIONS There was very low quality evidence that in patients with moderate to severe hypertension, partial agonists lowered peak BP by an average of 8/4 mmHg and reduced heart rate by five beats per minute. There was no evidence of a greater effect at doses higher than the initial doses. This estimate was probably exaggerated as it was subject to a high risk of bias. Based on the indirect comparison of the results in this review and two Cochrane reviews on angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), which also used similar inclusion criteria as this review, the BP lowering effect appeared to be less than the effect in patients with mild to moderate elevated BP who were taking ACE inhibitors and ARBs based on an indirect comparison. Withdrawals due to adverse effects were only reported in one trial so it is impossible to assess the harm of these drugs.

EFFECT OF NEBIVOLOL MONOTHERAPY OR COMBINATION THERAPY ON BLOOD PRESSURE LEVELS IN PATIENTS WITH HYPERTENSION: META-ANALYSIS OF 91 RANDOMIZED CONTROLLED TRIALS

The Efficacy of Nebivolol on Patient with Mild or Moderate Mssential Hypertension by Different Smbulatory Blood Pressure Monitoring Methods

Randomised Double-Blind Comparison of Placebo and Active Drugs for Effects on Risks Associated with Blood Pressure Variability in the Systolic Hypertension in Europe Trial.

EFFECT OF NIFEDIPINE GITS VERSUS RAMIPRIL ON HOME BLOOD PRESSURE VARIABILITY: PRELIMINARY RESULTS OF REVERENT RANDOMIZED TRIAL

Effects of Amlodipine and Other Classes of Antihypertensive Drugs on Long-Term Blood Pressure Variability: Evidence from Randomized Controlled Trials.

P114 SHORT-TERM EFFECTS OF BLOOD PRESSURE LOWERING DRUGS ON CARDIOVASCULAR EVENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED, PLACEBO-CONTROLLED, DOUBLED-BLIND TRIALS

PS-C12-8: BLOOD PRESSURE VARIABILITY IN PREVIOUSLY UNTREATED HYPERTENSIVE PATIENTS RANDOMIZED TO NIFEDIPINE GITS OR RAMIPRIL. REVERENT STUDY

Clinical pharmacokinetics of nebivolol: a systematic review

Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension.

Effects of Carvedilol Compared to Nebivolol on Insulin Resistance and Lipid Profile in Patients With Essential Hypertension

Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension.

Blood Pressure Variability Assessed by Office, Home, and Ambulatory Measurements Before and During Antihypertensive Drug Treatment: a Sub-Analysis of the REVERENT Randomized Trial

A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension.

Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials.

Benefits of Antihypertensive Pharmacologic Therapy and Blood Pressure Reduction in Outcome Trials

Efficacy and Effectiveness of Valsartan/amlodipine and Valsartan/amlodipine/hydrochlorothiazide in Hypertension: Randomized Controlled Versus Observational Studies

IDENTIFICATION OF HYPERTENSIVE PATIENTS WITH INCREASED BLOOD PRESSURE VARIABILITY USING DIFFERENT MEASUREMENT METHODS BEFORE AND AFTER TREATMENT: THE REVERENT TRIAL.

Modulation of TNF‐α, interleukin‐6, and interleukin‐10 by nebivolol–valsartan and nebivolol–lisinopril polytherapy in SHR rats

Endovascular baroreflex amplification and the effect on sympathetic nerve activity in patients with resistant hypertension: A proof-of-principle study

Levamlodipine Maleate Or Amlodipinebesylate For Treatment Of Hypertension: A Comparative Effectiveness Research

Effect of mindfulness-based meditation on blood pressure among adults with elevated blood pressure and hypertension: A systematic review of randomized controlled trials